Johnson & Johnson (JNJ) Offering Possible 9.17% Return Over the Next 6 Calendar Days

This article was originally published on this site

Johnson & Johnson’s most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $139.00 short put and a strike $134.00 long put offers a potential 9.17% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $139.00 by expiration. The full premium credit of $0.42 would be kept by the premium seller. The risk of $4.58 would be incurred if the stock dropped below the $134.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.

The RSI indicator is at 52.19 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Johnson & Johnson

The Opioid Epidemic Will Be A Yearslong Overhang For These Pharma Stocks
Thu, 13 Jun 2019 20:12:30 +0000
Ongoing litigation surrounding the opioid epidemic will be a yearslong overhang for several pharmaceutical companies like Teva Pharmaceutical, Mylan and Endo, an analyst said Thursday.

Johnson & Johnson Made the Right Call in Fighting Oklahoma Over Opioids, Analyst Says
Thu, 13 Jun 2019 14:56:00 +0000
Teva Pharmaceutical and Purdue Pharma both settled with Oklahoma over allegations they contributed to the state’s opioid crisis.

Johnson & Johnson and Cisco Directors Are Buying Up Stock
Thu, 13 Jun 2019 11:00:00 +0000
Lockheed CEO Marillyn Hewson made the first insider purchase of J&J stock this year, while Northrop Grumman Chairman Wes Bush bought up Cisco stock.

Jim Cramer: A Tale of Two Stocks
Wed, 12 Jun 2019 23:01:00 +0000
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

Pharma Giant Nears Two-Decade Low As Opioid Settlement Remains In Limbo
Wed, 12 Jun 2019 20:17:25 +0000
Teva Pharmaceutical skidded to a nearly two-decade low Wednesday amid confusion over its $85 million payment to Oklahoma to settle an ongoing opioid abuse case. J&J remains a defendant.

Be Sociable, Share!

Related Posts